HEAL Partnership Committee

About

The HEAL Partnership Committee (HPC) is a subgroup of the HEAL Multi-Disciplinary Working Group and provides assistance with defined tasks related to the development of new treatments for pain and addiction through Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, research. The HPC is responsible for making preliminary recommendations on the design of a template application and evaluation dossier for biopharmaceutical and device-based treatments to be tested through new clinical trials networks as part of the NIH HEAL Initiative. The working group incorporates input from the HPC into draft recommendations for NIH HEAL Initiative research, including on the process for the selection of assets for testing, the overall complement of assets to be tested at one time and the plan for expanding the portfolio to devices and biological treatments. Discussions of the HPC are made open to the public through videocasts and public meetings.

Meetings

The HEAL Partnership Committee met to discuss updates to the EPPIC-Net program and Foundation for the NIH informational interviews with committee members in regards to biomarker development.

Members

Rebecca Baker, Ph.D.

Director, NIH HEAL Initiative, Office of the Director, National Institutes of Health

John Dunlop, Ph.D.

Head of Research and Development, Neumora

Christopher Flores, Ph.D.

President and Chief Research and Development Officer, Doloromics

Steven Joffe, M.D.

Art and Ilene Penn Professor of Medical Ethics & Health Policy, Professor of Pediatrics, and Chair of the Department of Medical Ethics & Health Policy at the University of Pennsylvania Perelman School of Medicine

Walter Koroshetz, M.D.

Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health

John Marler, M.D.

Acting Clinical Deputy Director, Division of Neurological and Physical Medicine Devices, Center for Devices and Radiological Health, U.S. Food and Drug Administration

Mark Mintun, M.D.

Vice-President of Pain and Neurodegeneration Research, and Clinical Development Chief Medical Officer, Avid Radiopharmaceuticals

Richard Moscicki, M.D.

Executive Vice President and Science & Regulatory Advocacy Chief Medical Officer, Pharmaceutical Research and Manufacturers of America

Judith Paice, Ph.D., RN

Director, Cancer Pain Program, Division of Hematology-Oncology; Research Professor of Medicine, Northwestern University

Joni Rutter, Ph.D.

Acting Director, National Center for Advancing Translational Sciences, National Institutes of Health

Cheryl Stucky, Ph.D.

Marvin Wagner Endowed Chair, Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin

Dave Thomas, M.S.

Vice President of Industry Research, Biotechnology Innovation Organization

Christin Veasley

Cofounder and Director, Chronic Pain Research Alliance

Ashley Wallin Wittorf, M.S., M.B.A.

Senior Vice President; Executive Director, AdvaMed Accel Advanced Medical Technology Association

Clifford Woolf, M.D., Ph.D.

Professor of Neurology and Neurobiology, Harvard Medical School